A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy

Rationale: T-cell-redirecting bispecific antibodies (bsAbs) and trispecific antibodies (tsAbs) designed to recognize different epitopes or antigens have emerged as promising cancer therapies. Current approaches are all designed to include another antibody specific to the site of the primary antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Dong, Qi, Xuexiu, Wei, Xiaoyi, Zhao, Lijun, Wang, Xuechun, Li, Shuhong, Wang, Zhidong, Shi, Licai, Xu, Jiean, Hong, Mei, Liu, Zhong, Zhao, Lili, Wang, Xiankun, Zhang, Bo, Zhang, Yuhan, Wang, Feng, Cao, Yu J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706591/
https://www.ncbi.nlm.nih.gov/pubmed/36451856
http://dx.doi.org/10.7150/thno.75037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706591/
https://www.ncbi.nlm.nih.gov/pubmed/36451856
http://dx.doi.org/10.7150/thno.75037

Ejemplares similares